Staar Surgical Co. Stock
€39.03
Your prediction
Staar Surgical Co. Stock
Pros and Cons of Staar Surgical Co. in the next few years
Pros
Cons
Performance of Staar Surgical Co. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Staar Surgical Co. | -0.610% | -0.434% | -12.645% | -30.453% | 34.447% | -63.608% | - |
Orasure Tech | 3.130% | -3.347% | -9.412% | -4.545% | -37.987% | -40.830% | -36.232% |
scPharmaceuticals | -12.500% | -30.942% | -29.358% | -69.200% | -46.435% | -34.188% | - |
SI-BONE Inc | - | -7.246% | -8.571% | -45.299% | -32.632% | -50.388% | - |
Comments
News
STAAR Surgical Reports First Quarter 2024 Results
STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical to Report First Quarter Results on May 7, 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today